Asarina Pharma applies for the delisting of the company's shares
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on August 21, 2024 that the Company shall enter into voluntary liquidation. In light of this, the Company's board has today decided to apply for the delisting of the Company's shares from the Nasdaq First North Growth Market in Stockholm.
On 22 July 2024, Asarina published the board's proposal for an extraordinary general meeting to decide on voluntary liquidation of the Company. The proposal was submitted against the background that in mid-July 2024 the Company's partner process had not resulted in tenders for development collaborations or acquisition of the intangible assets related to Sepranolone, and that the conditions for a necessary capital raise for own development of Sepranolone were lacking. Since Asarina no longer conducts any operational activities, and that the Company's shareholders have decided on voluntary liquidation, the Company no longer meets the listing requirements on the Nasdaq First North Growth Market in Stockholm. The last day for trading in the Company's shares on Nasdaq First North Growth Market will be announced through a separate press release when the Company has received confirmation thereof from Nasdaq First North Growth Market.
Until the liquidation date, December 1, 2024, the Company's management and board will continue the work of finding buyers for Asarina's tangible and intangible assets.